Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Prognostic and predictive biomarkers for long COVID

Jennifer Frontera, MD, New York University Grossman School of Medicine, New York, NY, discusses current efforts to elucidate predicative biomarkers for long COVID. Simoa technology enables detection of existing neurodegenerative biomarkers in cerebrospinal fluid and plasma. Additional biomarkers of interest include markers of vascular damage such as VEGF and autoimmune markers, where detection of autoantibodies may be useful in a subset of patients who have developed autoimmune disorders de novo post COVID infection. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


NIH funding, WHO Brain Health Taskforce